CA
ORMP icon

Cliff Asness’s Oramed Pharmaceuticals ORMP Stock Holding History

Cliff Asness’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,954
Closed -$155K – 2267
2022
Q1 		$155K Sell
17,954
-2,021
-10% -$20.7K ﹤0.01% 2101
2021
Q4 		$285K Sell
19,975
-2,596
-12% -$54.3K ﹤0.01% 1996
2021
Q3 		$496K Buy
+22,571
New +$384K ﹤0.01% 1868

Other funds holding ORMP

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cliff Asness's ORMP Position: Q2 2022 in Review

Cliff Asness sold out of Oramed Pharmaceuticals (ORMP) in Q2 2022, closing a stake of 17,954 shares — an estimated $155K sold.

Cliff Asness first reported a position in ORMP in Q3 2021 and held it in 3 quarters. The position peaked at $496K in Q3 2021. 88 funds tracked by Wall St. Rank hold ORMP as of Q2 2022.

  • Cliff Asness reported no remaining Oramed Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Cliff Asness sold 17,954 Oramed Pharmaceuticals shares in Q2 2022, an estimated $155K.
  • Cliff Asness first reported a position in Oramed Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • Cliff Asness's Oramed Pharmaceuticals position peaked at $496K in Q3 2021.
  • 88 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2022.

Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.